Long-term treatment of patient with metastatic melanoma of the trunk

被引：0
|
作者：
Kempa-Kaminska, Natasza [1 ]
机构：
[1] Dolnoslaskie Ctr Onkol Wroclawiu, Oddzial Onkol Klin, Pl Hirszfelda 12, PL-53413 Wroclaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2018年 / 14卷
关键词：
immunotherapy; melanoma; vemurafenib; hepatotoxicity;
D O I：
10.5603/OCP.2018.0063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Currently there has been a huge development in melanoma therapy. There are drugs with high efficacy, but also with a completely new toxicity profile. Below is a case report of a patient treated for metastatic melanoma of the body. Treatment included vemurafenib and immunotherapy in the form of pembrolizumab, a monoclonal antibody blocking PD-1 receptor. Among toxicity, dermatological effects of vemurafenib treatment and hepatotoxicity during immunotherapy were observed mainly in case of treatment with vemurafenib. The applied treatment allowed for several years of survival of the patient in good general condition.
引用
收藏
页码：A19 / A22
页数：4
相关论文
共 50 条
  • [1] Long-term Survival in Metastatic Malignant Melanoma: Ipilimumab Followed by Vemurafenib in a Patient with Brain Metastasis
    Balakan, Ozan
    Suner, Ali
    Yigiter, Remzi
    Balakan, Tuba
    Sirikci, Akif
    Sevinc, Alper
    INTERNAL MEDICINE, 2012, 51 (19) : 2819 - 2823
  • [2] Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient
    Wu, Richard C.
    Newman, William
    Patanowitz, Liron
    Branstetter, Barton F.
    Amankulor, Nduka
    Tarhini, Ahmad A.
    IMMUNOTHERAPY, 2020, 12 (11) : 763 - 769
  • [3] Evolving impact of long-term survival results on metastatic melanoma treatment
    Michielin, Olivier
    Atkins, Michael B.
    Koon, Henry B.
    Dummer, Reinhard
    Ascierto, Paolo Antonio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [4] Long-term survival of a metastatic cerebral melanoma
    Banayan, A
    Vital, C
    NEUROCHIRURGIE, 1998, 44 (04) : 275 - 277
  • [5] Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
    Charlée Nardin
    Sophie Borot
    Marie-Astride Beaudoin
    Françoise Cattin
    Eve Puzenat
    Anne-Sophie Gauthier
    Franck Schillo
    Christophe Borg
    François Aubin
    Investigational New Drugs, 2019, 37 : 375 - 377
  • [6] Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
    Nardin, Charlee
    Borot, Sophie
    Beaudoin, Marie-Astride
    Cattin, Francoise
    Puzenat, Eve
    Gauthier, Anne-Sophie
    Schillo, Franck
    Borg, Christophe
    Aubin, Francois
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 375 - 377
  • [7] Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo
    Fukumoto, Takeshi
    Fujiwara, Susumu
    Sakaguchi, Masanobu
    Oka, Masahiro
    Kiyota, Naomi
    Ejima, Yasuo
    Nakajima, Koichi
    Nishigori, Chikako
    EUROPEAN JOURNAL OF DERMATOLOGY, 2017, 27 (02) : 177 - 178
  • [8] Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
    Soerensen, Anne Vest
    Ellebaek, Eva
    Bastholt, Lars
    Schmidt, Henrik
    Donia, Marco
    Svane, Inge Marie
    CANCERS, 2020, 12 (09) : 1 - 11
  • [9] Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications
    Grossmann, Kenneth F.
    Margolin, Kim
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (03) : 181 - 191
  • [10] Patient preferences for treatment of metastatic melanoma
    Mansfield, Carol
    Ndife, Briana
    Chen, Joyce
    Gallaher, Kathleen
    Ghate, Sameer
    FUTURE ONCOLOGY, 2019, 15 (11) : 1255 - 1268
12345